Skip to main content
Premium Trial:

Request an Annual Quote

VC Spending on -omics Shops Slides 25 Percent in Q1, But Proteomics, Genomics Grows

NEW YORK (GenomeWeb News) — The flow of venture capital to the multivariate -omics disciplines slowed by more than a quarter in the first three months of 2007 compared to the same period in 2006, according to a GenomeWeb Daily News roundup of companies that disclosed receiving investments.
 
However, private equity financing to companies that sell or provide services for genomic or proteomic applications increased year over year.
 
VC investment in all privately held -omics companies covered by GenomeWeb Daily News fell nearly 26 percent to $63.2 million spread among five deals in the first quarter of 2007 from $79.6 million spread among nine deals in the same period last year.
 
But companies dealing in genomic wares saw a 138-percent increase in VC investment, netting $20.5 million in the first quarter of 2007 compared with $8.6 million year over year.
 
Also, investment in proteomic tool companies grew 150 percent to $48.7 million from $19 million in the first quarter last year.
 
Companies closing private-equity rounds in the first quarter of 2007 were Genizon BioSciencesAutoGenomicsDevgen, GenTel BioSciences, and Oxford Genome Sciences.
 
Companies closing private-equity rounds in the first quarter of 2006 were DeltaDotBioTroveCoda Genomics, Precision TherapeuticsDecision Biomarkers, EraGenIntrexonGuava Technologies, and Cetek.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.